|Bid||0.00 x 800|
|Ask||36.48 x 3200|
|Day's Range||36.24 - 36.54|
|52 Week Range||30.20 - 37.61|
|PE Ratio (TTM)||158.78|
|Earnings Date||Jul 23, 2018 - Jul 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.40|
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
QIAGEN N.V. today announced that it welcomes new guidelines from the American Academy of Pediatrics that recommend screening at-risk children as young as two years old for latent tuberculosis infection.
QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN N.V. today announced a partnership with Freenome, a leading artificial intelligence genomics company, to accelerate the development and commercialization of next-generation sequencing tests to enable precision medicine in cancer treatment.
A Relative Strength Rating upgrade for Qiagen shows improving technical performance. Will it continue?
QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection. The inclusion on the list comes as the WHO and other organizations like the US Centers for Disease Control (CDC), the International Panel Physicians Association (IPPA) and others have recommended to include IGRA’s such as QuantiFERON-TB Gold Plus. The World Health Organization (WHO) published the first edition of the Model List of Essential In Vitro Diagnostics (EDL) in May 2018, in recognition that IVDs are an essential component to advance universal health coverage, address health emergencies, and promote healthier populations.
On Tuesday, May 15, 2018, US markets saw broad based losses with all sectors finishing the trading sessions in red. All you have to do is sign up today for this free limited time offer by clicking the link below.
Frankfurt Prime Standard: QIA) announces that it will initiate the repurchase of a first tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 15, 2018 until August 20, 2018, at the latest, a first tranche of up to 1.65 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
The Venlo, Netherlands-based company said it had net income of 14 cents per share. Earnings, adjusted for non-recurring costs, came to 26 cents per share. The results beat Wall Street expectations. The ...
QIAGEN N.V. announced results of operations for the first quarter, exceeding goals for net sales and adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
QIAGEN N.V. today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
QIAGEN N.V. today announced the launch of QIAstat-Dx® in Europe, providing a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology and other diseases.
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2018 on Wednesday, May 2 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
QIAGEN N.V. today launched two novel liquid biopsy panels to evaluate circulating tumor cells in the growing field of research into molecular mechanisms in prostate and lung cancers.
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN N.V. announced today that its QuantiFERON-TB® Gold Plus , the gold standard in accurate, cost-effective testing for latent tuberculosis infection, has been endorsed for immigration medical screening by the International Panel Physicians Association .